ANA Therapeutics

OverviewSuggest Edit

ANA Therapeutics is a company that develops a corona vaccine. The company provides a well-tolerated compound, niclosamide that has the potential to be a needed treatment to help individuals who contract the novel coronavirus.

Latest Updates

Employees (est.) (Nov 2020)2
Cybersecurity ratingAMore

ANA Therapeutics Financials and Metrics

Summary Metrics

Founding Date


ANA Therapeutics total Funding

$5 m

ANA Therapeutics latest funding size

$5 m

Time since last funding

4 months ago

ANA Therapeutics investors

ANA Therapeutics's latest funding round in August 2020 was reported to be $5 m. In total, ANA Therapeutics has raised $5 m
Show all financial metrics

ANA Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

ANA Therapeutics Online and Social Media Presence

Embed Graph

ANA Therapeutics News and Updates

ANA Therapeutics Announces U.S. FDA Clearance Of IND Application To Initiate Clinical Trial Of Niclosamide In COVID-19 Patients

In early March, at the outset of the coronavirus pandemic in the U.S., ANA pivoted their business to determine the efficacy of niclosamide for COVID-19 and quickly raised over $5 million to lead the first U.S.-based clinical trial for niclosamide as a COVID-19 treatment. Investors in ANA's seed roun…

ANA Therapeutics Frequently Asked Questions

  • When was ANA Therapeutics founded?

    ANA Therapeutics was founded in 2020.

  • How many employees does ANA Therapeutics have?

    ANA Therapeutics has 2 employees.

  • Who are ANA Therapeutics competitors?

    Competitors of ANA Therapeutics include RubrYc Therapeutics, Tempest Therapeutics and CanSino Biologics.